NEW YORK (
CHANGE IN RATINGS
upgraded to hold at TheStreet Ratings.
downgraded at Baird from Outperform to Neutral, Robert Baird said. $95 price target. End-market exposure remains challenging and long-term growth targets may need to be lowered.
upgraded at BofA/Merrill from Underperform to Buy, Bank of America/Merrill Lynch said. $36 price target. Macro outlook makes defensive stocks more attractive.
rated new Sell at Cantor Fitzgerald. $11 price target. Company trades at a premium to its peers, but faces long-term competitive issues.
rated new Equal-weight at Morgan Stanley. Valuation call.
downgraded to sell at TheStreet Ratings.
upgraded at BofA/Merrill from Underperform to Neutral, Bank of America/Merrill Lynch said. $3.50 price target. Company has softened its leverage outlook, which should help support the dividend.
upgraded at UBS to Buy from Neutral, UBS said. $225 price target. Pullback on Amazon anxiety enables entry into high quality growth stock.
Jack in the Box
upgraded at Jefferies to Buy from Hold, Jeffeies said. $31 price target. Unlocking value and growth.
upgraded at Morgan Stanley from Equal-weight to Overweight, Morgan Stanley said. $42 price target. Recent pullback has created a buying opportunity. Company can post double-digit dividend growth and is yielding 4%.
(NAV - Get Report)
downgraded at Deutsche from Buy to Hold, Deutsche Bank said. $35 price target. Company posted a surprise loss and has limited near-term visibility.
upgraded at BofA/Merrill from Neutral to Buy. $57 price target. More bullish on Krypolis prospects, following ASCO.
(PLL - Get Report)
upgraded at JP Morgan from Underweight to Neutral, JP Morgan said. Valuation call, based on a $55 price target.
upgraded at Baird from Neutral to Outperform, Robert Baird said. $124 price target. Growth should accelerate in the second half of the year.
(STI - Get Report)
upgraded at Argus from Hold to Buy, Argus said. $30 price target. Company is leveraged to improving economic conditions in Florida.
STOCK COMMENTS / EPS CHANGES
(HAL - Get Report)
estimates cut at Sterne Agee through 2013, Sterne Agee said. Higher guar costs will hurt margins. Buy rating and $48 price target.